A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Registry for Patients with Short Bowel Syndrome
Sponsor: Shire-NPS Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAR6066
U.S. Govt. ID: NCT01990040
Contact: Shilpa Ravella, MD: 212-305-3839 / sr3236@cumc.columbia.edu
Additional Study Information: This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.
This study is closed
Shilpa Ravella, MD
Do You Qualify?
Do you or your child have Short Bowel Syndrome (SBS)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Shilpa Ravella, MD